Arthur F Ryan sold $79k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $785.50, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleDirector
- +9Trade size$79k at market
- 0Share of holdings soldSold 0.6% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m -21.2%, 6m +7.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001187443-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -7 | $777.46 | $5,442 | 17,796 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $778.30 | $1,557 | 17,794 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -5 | $779.69 | $3,898 | 17,789 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -3 | $780.69 | $2,342 | 17,786 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $781.21 | $1,562 | 17,784 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $782.62 | $1,565 | 17,782 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -10 | $783.62 | $7,836 | 17,772 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -9 | $784.48 | $7,060 | 17,763 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -11 | $785.48 | $8,640 | 17,752 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -7 | $786.61 | $5,506 | 17,745 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $787.34 | $1,575 | 17,743 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -20 | $788.96 | $16k | 17,723 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -20 | $789.28 | $16k | 17,703 | Mar 3, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% | |
| 19Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.